

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-12. (Canceled)

13. (Currently amended) A method of selectively inhibiting an angiogenic process promoted by a first angiogenic factor, but not the angiogenesis process promoted by a second angiogenic factor, comprising administering to a cell exposed to both factors an effective amount of STC-1 (SEQ ID NO: 2) ~~or a variant thereof~~, wherein the STC-1 ~~or a variant thereof~~ inhibits at least one step of the angiogenic process promoted by the first angiogenic factor but not the second angiogenic factor,

wherein the first angiogenic factor is hepatocyte growth factor and the second angiogenic factor is selected from the group consisting of: fibroblast growth factor and vascular endothelial growth factor, and

wherein the angiogenic process is cell migration.

14. (Original) The method of claim 13, wherein the first and second angiogenic factors both are capable of inducing endogenous expression of STC-1.

15-18. (canceled)

19. (Currently amended) The method of claim 13, wherein STC-1 ~~or variant thereof~~ does not inhibit cell proliferation.

20-29. (Canceled)